ERRATUM



Erratum to Clinical management and survival outcomes of patients with different molecular subtypes of diffuse gliomas in China (2011–2017): a multicenter retrospective study from CGGA

Kenan Zhang¹, Xing Liu², Guanzhang Li^{1,3}, Xin Chang⁴, Shouwei Li⁴, Jing Chen¹, Zheng Zhao¹, Jiguang Wang^{5,6,7}, Tao Jiang^{1,3}, Ruichao Chai^{1,2,5}

¹Department of Molecular Pathology, Beijing Neurosurgical Institute, Capital Medical University, Beijing 100070, China; ²Department of Neuropathology, Beijing Neurosurgical Institute, Capital Medical University, Beijing 100070, China; ³Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing 100070, China; ⁴Department of Neurosurgery, Beijing Sanbo Brain Hospital, Capital Medical University, Beijing 100093, China; ⁵Division of Life Science and State Key Laboratory of Molecular Neuroscience, Department of Chemical and Biological Engineering, The Hong Kong University of Science and Technology, Clear Water Bay, Kowloon, Hong Kong SAR 999077, China; ⁶Hong Kong Center for Neurodegenerative Diseases, Hong Kong Science Park, Hong Kong SAR 999077, China; ⁷HKUST Shenzhen-Hong Kong Collaborative Innovation Research Institute, Futian, Shenzhen 518057, China




Figure 2C Kaplan-Meier estimation of the overall survival of patients with recurrent DG classified according to molecular subtypes.

In the published version of **Figure 2**¹, an error appeared in **Figure 2**C on page 1468. In **Figure 2**C, the Kaplan-Meier estimation of the overall survival of patients with recurrent DG classified according to molecular subtypes was mistakenly covered by the curves of patients with primary DGs during the figure layout process, while the number statistic under the figure is correct. **Figure 2**C has been updated to correct this mistake. The error does not affect the conclusions of this article. We apologize for the error and for any confusion that it might have caused.

Reference

 Zhang K, Liu X, Li G, Chang X, Li S, Chen J, et al. Clinical management and survival outcomes of patients with different molecular subtypes of diffuse gliomas in China (2011–2017): a multicenter retrospective study from CGGA. Cancer Biol Med. 2022; 19: 1460-76.

Correspondence to: Ruichao Chai and Tao Jiang
E-mail: chairuichao_glia@163.com and taojiang1964@163.com
Received June 27, 2023; accepted June 29, 2023.
Available at www.cancerbiomed.org
©2023 Cancer Biology & Medicine. Creative Commons
Attribution-NonCommercial 4.0 International License

Cite this article as: Zhang K, Liu X, Li G, Chang X, Li S, Chen J, et al. Erratum to Clinical management and survival outcomes of patients with different molecular subtypes of diffuse gliomas in China (2011–2017): a multicenter retrospective study from CGGA. Cancer Biol Med. 2023; 20: 537. doi: 10.20892/j.issn.2095-3941.2023.0227